乳腺癌p53、c－erbB－2基因蛋白、表皮生长因子受体与雌、孕激素受体的表达及其临床意义

p53, c-erhB-2, EGFR, ER and PgR expression in breast cancer and its clinical significance

应用免疫组化ＡＢＣ法检测１００例乳腺癌和１００例乳腺良性病变组织中ｐ５３、ｃ－ｅｒｂＢ－２、ＥＧＦＲ与ＥＲ、ＰｇＲ的表达。结果显示：乳腺癌各种标记阳性率均高于乳腺良性病变；ＥＲ阳性率在５０岁以上组高于５０岁以下组（Ｐ＜０．０５）；不同病理学类型中各种标记的阳性率亦存在一定差异，乳腺癌中ｐ５３、ｃ－ｅｒｂＢ－２、ＥＧＦＲ和ＥＲ及ＰＲ的表达呈显著负相关（Ｐ＜０．０１），可能成为判断乳腺癌治疗和预后的重要标志。

The ABC immunohistochemical method was used to detect p53, c-erbB-2, EGFR,ER and PgR in 100 cases of breast cancer and 100 cases of benign breast lesions. The results suggested that the positive rate of all examined immunohistochemical markers was higher in carcinomas than in benign lesions. At the same time, ER positive rate among those, over 50 years old was significantly higher than that in under 50 group (P<0.05).We also got a conclusion that higher expression of p53 or EGFR (P<0.01),or c-erbB-2 (P<0.005) may serve as an indicator for poor pathological differentiation and poor clincal prognosis, while higher ER of PgR (P<0.005), an indicator for well prognosis.